Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07605923 · ClinicalTrials.gov registry record · Phase 4
Methylprednisolone Addition to Multimodal Pain Regimens After Anterior Cruciate Ligament Reconstruction
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Not yet
- Registry status
- Phase 4
- Development phase
- 64
- Enrollment target
NCT07605923: Clinical Trial Phase 4 study, sponsored by University of Alabama at Birmingham.
NCT07605923 is a Phase 4 study that has not yet begun recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 64 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07605923, a Phase 4 study, has not yet begun recruiting, sponsored by University of Alabama at Birmingham.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 64 participants
- Enrollment target
Study Summary
Patients who are being seen for ACL tears will be approached in the UAB Orthopedic Clinic. Included patients will be those aged 14-65 undergoing ACL Reconstruction. Excluded patients will be those with contraindications to corticosteroids. If the patient meets the criteria and agrees to participate, then the consent form will be signed, and the patient will be enrolled. Enrolled patients will be randomized to one of two groups. Patients in the treatment group will receive a 4 mg oral 6-day methylprednisolone taper in addition to standard post-operative pain control. Patients in the control group will receive standard post-operative pain control. All patients will receive the surgeon's standard ACL postoperative multimodal pain regimen. Endpoints will include narcotic consumption assessed daily and at one week post-op through a patient self-reported diary. The VAS pain score will be collected each day for the first week. Secondary endpoints will include range of motion and patient-reported outcomes, including IKDC, KOOS Jr, Tegner Activity Scale, ACL-RSI, and PROMIS Global collected at baseline, 2 weeks, 6 weeks and 3 months. All outcomes will be collected through PatientIQ.
Primary Outcome
Paricipants will be assessed on the average amount of pain medication taken on a daily basis.
Interventions
- DRUG Methyl Prednisolone (MP)
- DRUG Standard Post-Operative Pain Control
- COMBINATION_PRODUCT Surgeon's Standard ACL Postoperative Regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2026-09 |
| Est. Completion | 2031-08 |
| Phase | Phase 4 |
What is known before NCT07605923 opens enrollment
NCT07605923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 3 interventions - of which Methyl Prednisolone (MP) is the first listed.
NCT07605923 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07605923 about?
NCT07605923 is a clinical study titled "Methylprednisolone Addition to Multimodal Pain Regimens After Anterior Cruciate Ligament Reconstruction". Patients who are being seen for ACL tears will be approached in the UAB Orthopedic Clinic. Included patients will be those aged 14-65 undergoing ACL Reconstruction. Excluded patients will be those with contraindications to corticosteroids. If the patient meets the criteria and agrees to participate,...
What is the current status of trial NCT07605923?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 2026-09. Estimated completion is 2031-08.
What interventions are being tested in trial NCT07605923?
The interventions under investigation include: Methyl Prednisolone (MP) (DRUG), Standard Post-Operative Pain Control (DRUG), Surgeon's Standard ACL Postoperative Regimen (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07605923?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07605923's enrollment target sits among peer trials
64 1098th of 2000 higher than 895 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia